Autoinflammatory & rare systemic diseases
Early longitudinal proteomic changes during sirolimus therapy in tocilizumab-refractory idiopathic multicentric Castleman disease
Authors' conclusion
Early and coordinated decreases in immune-inflammatory mediators were observed during sirolimus therapy in tocilizumab-resistant iMCD, extending beyond the IL-6 axis to encompass IFN-γ, TNF-α, and chemokine signalling.
Study context
- Population
- Patient with tocilizumab-resistant idiopathic multicentric Castleman disease (iMCD) treated with sirolimussingle patient
- Participants
- 1 participants
- Outcome
- Early treatment-associated changes in circulating immune mediators after sirolimus initiation
- Follow-up
- Baseline and weeks 8, 12, and 16
Methodological detailspredefined translational sub-analysis of a placebo-controlled exploratory trial, longitudinal serum proteomic profiling (RayBiotech L-1000 antibody array, ∼1,000 proteins), gene set enrichment analysis (GSEA)
- Predefined translational sub-analysis of a placebo-controlled exploratory trial
- Longitudinal serum proteomic profiling (RayBiotech L-1000 antibody array, ∼1,000 proteins)
- GSEA
Main finding
As reported in the abstract
Changes in circulating immune mediators during sirolimus therapy
- Consistent monotonic decreases from baseline through week 12 of six mediators: CCR5, ICAM-1, RANTES, S100A8/A9, CD40 ligand, OX40 ligand
- 6
Original publication
Early longitudinal proteomic changes during sirolimus therapy in tocilizumab-refractory idiopathic multicentric Castleman disease. Rheumatology (Oxford). Published 14 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →